Skip to main content

Market Overview

Recap: Syndax Pharmaceuticals Q1 Earnings


Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) rose in after-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were up 3.57% year over year to ($0.54), which beat the estimate of ($0.65).

Revenue of $379,000 unchanged by 0.00% year over year, which beat the estimate of $220,000.


Syndax Pharmaceuticals Sees Q2 Research 7 Development Expenses To be $30M-$35M And FY21 $90M-$100M

Conference Call Details

Date: May 11, 2021

Time: 04:30 PM

ET Webcast URL:

Price Action

Company's 52-week high was at $27.85

Company's 52-week low was at $13.02

Price action over last quarter: down 28.18%

Company Profile

Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.


Related Articles (SNDX)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings